Article Information
PubMed
Print ISSN
Online ISSN
History
- Received December 16, 2010
- Accepted March 2, 2011
- Published online May 16, 2011.
Article Versions
- Earlier version (March 4, 2011 - 09:22).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Dilek Iusuf,
- Sebastiaan F. Teunissen,
- Els Wagenaar,
- Hilde Rosing,
- Jos H. Beijnen and
- Alfred H. Schinkel
- Division of Molecular Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands (D.I., E.W., A.H.S.); and Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands (S.F.T., H.R., J.H.B.)
- Address correspondence to:
Dr. Alfred H. Schinkel, The Netherlands Cancer Institute, Division of Molecular Biology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands, E-mail: a.schinkel{at}nki.nl
Partial results of this study were previously presented as follows: Iusuf D, Teunissen B, Poller B, Sparidans RW, Wagenaar E, Beijnen JH, and Schinkel AH (2010) Endoxifen brain accumulation is restricted mainly by P-glycoprotein (ABCB1), whereas axitinib brain accumulation is controlled by both ABCG2 (BCRP) and P-glycoprotein. ISSX Workshop on Genetic Polymorphisms in Drug Disposition; 2010 April 11–13; Indianapolis, IN. International Society for the Study of Xenobiotics, Washington, DC.
D.I. and S.F.T. contributed equally to this work.